3
Announcements
Trials
Browse
Landscape
Phase
Phase NA
7
Phase 1/2
1
Status
Recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Gynecologic
1
Conditions
Triple Negative Breast Neoplasms
2
Neoplasm Metastasis
2
Carcinoma, Non-Small-Cell Lung
2
Breast Neoplasms
2
Recurrence
1
Ovarian Neoplasms
1
Gliosarcoma
1
Glioblastoma
1
Fallopian Tube Neoplasms
1
Central Nervous System Neoplasms
1
Carcinoma, Ovarian Epithelial
1
Carcinoma, Hepatocellular
1
Brain Neoplasms
1
Interventions
Carboplatin
46
Paclitaxel
31
pembrolizumab
25
Cyclophosphamide
24
Nivolumab
14
Bevacizumab
14
Topotecan
12
Gemcitabine
12
liposomal doxorubicin
11
Filgrastim
11
Cisplatin
11
fludarabine
10
Peripheral Blood Stem Cell Transplantation
10
olaparib
8
aldesleukin
7
durvalumab
6
Oxaliplatin
6
Ipilimumab
6
Interleukin-2
6
Docetaxel
6
niraparib
5
epacadostat
5
cemiplimab
5
Ifosfamide
5
Fulvestrant
5
rucaparib
4
poly ICLC
4
pazopanib
4
avelumab
4
atezolizumab
4
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 1/2
×
Ovarian Neoplasms
×
Palliative Care
×
Clear all
NCT07617753
2026-06-01
DUAL-OV-CAR-NK
Beijing Biotech
Phase 1/2
Recruiting
36 enrolled